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Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity,
mortality, disability, and cost globally and in the United States. Various sources point to
women experiencing greater morbidity, increased health care resource use and higher
incidence of mortality resultant from COPD. While exact causality is not fully
understood, it is possible that social bias towards COPD in women impacting screening
and timely diagnosis may be a contributing factor. This current investigation involved the
social ecological model. In this cross-sectional secondary analysis of Behavioral Risk
Factor Surveillance System, 2017 data, differences in screening through use of breathing
testing among 6334 males and females who have knowledge of COPD were assessed
through descriptive statistics, Pearson’s chi-squared test, and binomial logistic regression
(BLR). Bivariate analysis indicated a marginally significant association between sex and
participation in breathing tests (χ2 = 3.44, p = 0.063), disproportionately impacting
women who used tests less. According to BLR models, females were 15.9% more likely
not to take the breathing tests compared to males (OR = .841, CI 95%: 0.739-0.961)
adjusted for COPD symptoms, and females were 11.7% more likely not to take the
breathing test when controlling for healthcare coverage, but this result was marginally
significant (OR=.883 CI 95%: .775-1.007). This study can offer insight into the use and
patterns of breathing testing among the US population while further describing potential
gaps in care, serving as catalyst towards driving necessary education, policy development
and broader social change.
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Section 1: Foundation of the Study and Literature Review
World Health Organization, global authority in public health, has described
chronic obstructive pulmonary disease (COPD) as one of the leading causes of morbidity,
mortality, and cost globally and the United States (World Health Organization [WHO],
2017). In 2016, the global burden was estimated at 251 million cases, with a US footprint
of roughly 27 million as described by the Centers for Disease Control and Prevention
(CDC), US authority in public health (Centers for Disease Control [CDC], 2016). Little is
understood about specific variances within the general population; however, mortality
due to disease is dense in low-middle income countries, which is hypothesized to be
somewhat related to environmental high levels of indoor and outdoor air pollution as well
as exposure to tobacco (Quaderi, 2018). The American Thoracic Society suggests the
next 15 years will elevate COPD as the primary killer globally when considering current
societal exposure to tobacco and indoor air pollution while superimposing an aging
population (ATS, 2018).
COPD is known to follow prolonged exposure to noxious particles, complicated
by the slow onset of symptoms which progress in severity and persistency over time. For
patients, symptoms of shortness of breath and cough take time to be recognized;
typically, activity modification is implemented prior to seeking medical attention. These
complexities contribute to patients’ limited understanding of prevalence and diagnostic
patterns; therefore, clinical interaction is necessary for testing and formal assessment.
Moreover, COPD was perceived to be an illness mainly observed in men; therefore,
inherent biases continue to burden attitudes towards women (WHO, 2019).

2
This study explored relationship between sex and subsequent diagnostic patterns
in COPD to ascertain whether a sex bias, specifically regarding women, towards
breathing testing exists. CDC’s Behavioral Risk Factor Surveillance System (BRFSS)
2017 dataset was utilized for this secondary analysis to assess occurrence of diagnostic
testing between males and females who were told by healthcare providers that they have
COPD. This study should guide policymakers, clinicians, researchers, advocacy groups,
and patient educators towards recognizing these intrinsic biases, their implication for
patients’ disease management, and quality of life. Moreover, necessary actions should be
taken to reduce time to diagnosis and improvement in outcomes for all patients with
COPD.
Section 1 explores rationale for investigation supported by an extensive literature
review. Moreover, methodology and application to theory and practice are introduced.
The following sections include the problem statement, purpose of the study, research
questions and hypotheses, theoretical foundation for the study, nature of the study,
literature search strategy, literature review & variables, definitions, assumptions, scope
and delimitations, significance, summary, and conclusions.
Problem Statement
COPD has recently demanded attention from a multitude of stakeholders on a
global and local scale, as burden of illness is alarming. Complicating the issue is the lack
of consensus regarding capturing accurate prevalence of COPD prevalence (DiazGuzman, 2014). Because the illness is progressive, while symptoms of shortness of
breath may have alternate causality, diagnostic testing through the use of pulmonary
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function testing is recommended by governing expert panels (GOLD, 2020). Spirometry
is a functional breathing assessment with minimal invasiveness; therefore, it is unlikely
that early detection initiatives would cause harm. United States Preventative Task Force
[USPTF] (2016) suggests that asymptomatic adults should not undergo screening even if
at risk; instead, active “case finding” should be practiced by clinicians. Active case
finding would prompt a clinician to recommend breathing tests if a patient has active and
burdensome symptoms with a known risk factor. Out of the estimated 24 million
individuals in the US with signs and symptoms of COPD, only 15.7 million actually have
an accurate diagnosis (NIH, 2018). Underdiagnoses is problematic, as patients may be
likely to delay treatment, suffering potentially negative outcomes. Chronic Respiratory
Disease Collaborators (GBD) (2017) found an increase of over 11% in death causalities
due to COPD since 1990, while overall age-related deaths have steadily declined.
American population does not experience COPD homogeneously; in fact, several
societal trends are observed. Centers for Disease Control and Prevention (2012) suggests
that Hispanics are less likely to report COPD in comparison to non-Hispanic whites and
African Americans at 4% vs. 6.3% and 6.1%, respectively. Education level and
employment status serve as protective; those with greater degrees of academic
achievement and employment experience less disease burden. Disease patterns parallel
those of population segments with higher observed incidents of smoking (CDC, 2012).
Sex alone is a significant risk factor for both morbidity and mortality in COPD, as
women are more likely to die as a result of the illness (Mannino, 2013).
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Within the medical community, COPD was historically viewed as a disease
predominately affecting Caucasian males (Dransfield, 2006). Within the century,
cigarette consumption in the United States experienced rapid uptake by predominately
Caucasian males during both world wars and the Great Depression. Following 1964
Surgeon General Report, steady declines in men were observed (U.S. Department of
Health and Human Services [DHHS], 2014). In women, prevalence of smoking varied
over the same time frame from 5-40%. Use of cigarettes by women, according to
multiple surveys, consistently demonstrated a lower consumption rate (Office on
Smoking and Health (US, 2001). Aside from social biases and behavioral trends, women
are more likely to report symptoms and die as a result of COPD (NIH, 2018). COPDrelated mortality decreased in men by 22 % between 2000 and 2014; progress in women
decreased by 3.8% over the same period (CDC, 2018). Little evidence is available to
describe illnesses specifically experienced by women and access to accurate diagnosis.
This gap in understanding of social stigmatization of disease in women warrants further
investigation to fully describe societal patterns and ramifications. The intent of this study
was to evaluate differences in terms frequency of occurrences of diagnostic testing via
breathing tests between men and women.
Purpose of the Study
Considering the immense variabilities in diagnostic patterns of COPD as well as
potential impacts of sex bias, the objective of this investigation was to describe these
patterns particularly as they relate to women at risk. This quantitative, cross-sectional
analysis interrogated the BRFSS 2017 database to describe diagnostic patterns among

5
men and women; specifically, subjects who have been told by healthcare providers that
they have COPD and response to breathing tests construct. Examination of these findings
should inform researchers, clinicians, public health practitioners, and policy makers in
driving social change. This may include education across societal sectors, working
towards population screening, timely diagnosis and intervention for all patients at risk.
Research Questions and Hypothesis
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) promotes
spirometry as a necessary diagnostic assessment contributing to the verification of COPD
diagnosis. However, societal and organizational dynamics present potential barriers
which disproportionally affect women. This study was intended to examine the
prevalence of breathing tests among men and women who have been told by healthcare
providers that they have COPD. It is hypothesized that less diagnostic testing will be
observed in women, with potential greater presence of symptoms and activity limitations.
This study interrogated the 2017 BRFSS cohort, a national database surveying
over 500,000 US adults across 50 states, thereby supporting generalizability of the study.
RQ1: Are there differences in terms of use of breathing tests between men and
women who have been told by clinicians they have COPD?
Ho1: There are no differences in terms of use of breathing tests between males and
females who have been by clinicians told they have COPD.
Ha1: There are difference in terms of use of breathing tests between males and
females who have been told by clinicians they have COPD.
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RQ2: Are there differences in terms of use of breathing tests between men and
women who have been told by clinicians they have COPD and experience cough, phlem,
and shortness of breath?
Ho2: There are no differences in terms of use of breathing tests between males and
females who have been told they have COPD and experience cough, phlem, and
shortness of breath.
Ha2: There are difference in terms of use of breathing tests between males and
females who have been told they have COPD and experience cough, phlem, and
shortness of breath.
RQ3: Are there differences in terms of use of breathing tests between men and
women who have been told by clinicians they have COPD and access to healthcare?
Ho3: There are differences in terms of use of breathing tests between males and
females who have been told by clinicians they have COPD and access to healthcare.
Ha3: There are differences in terms of use of breathing tests between males and
females who have been told by clinicians they have COPD and access to healthcare.
Theoretical Foundation for the Study
Screening behaviors of clinicians and patients are driven by beliefs and attitudes,
further reinforced by social and policy constructs. A model for this work must
adequately represent the complexity of COPD diagnostic patterns and societal influences.
Social Ecological Model (SEM) was applied to the study. Urie Bronfenbrenner in the
1970s developed the SEM to describe drivers of human development. Later, model
further evolved into a theoretical framework delineating external influences on human
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beliefs and actions (Kilanowski, 2017). This theoretical framework is grounded on
individual attitudes and beliefs towards an idea; recognizing influence of interpersonal,
organizational, community, and policy dynamics surrounding phenomena. SEM
framework has been applied in many public health research and intervention initiatives to
describe various phenomena while stimulating process improvement. The CDC has
applied this model towards stimulating and driving participation in the National Breast
and Cervical Cancer Early Detection Program (NBCCEDP) for greater participation in
screening.
The SEM can be implemented to describe flow of perception within the system
involving sex-based trends in COPD screening. Recognizing systemic societal concerns
involving COPD as they relate to women is essential.

Figure 1. Social Ecological Model applied to societal biases in COPD
Nature of the Study
For this investigation, a cross-sectional, secondary, quantitative methodology was
applied. CDC’s BRFSS was established in the 1980s with the intent of collecting self-
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reported behaviors and risks across the US populace; since its initiation with 15
participating states, data is collected via monthly telephone surveys across 50 states as
well as the District of Columbia, American Samoa, Palau, Puerto Rico, US Virgin
Islands, and Guam. With more than 500,000 case interviews for this broad population, ,
this data set is ideal for investigation and observation of potential trends. Participants in
the survey were randomly selected adults who were 18 and older. A cross-sectional
analysis was selected for this investigation due to the observational nature of the study.
A descriptive analysis of the population was completed.
Literature Search Strategy
For this investigation, three primary databases, PubMed, Medline and ProQuest,
were used with the assistance of two libraries (AstraZeneca Library Portal and Walden
University). Key words used for the literature review were chronic obstructive
pulmonary disease, COPD, epidemiology, morbidity, mortality, healthcare cost, smoking,
tobacco related illness, diagnosis, pulmonary function testing, sex, gender, social
ecological model, and public policy. I concentrated on recent literature published
between 2013 and 2019. Studies describing COPD and diagnostic journeys experienced
by women are significantly lacking, as is information about sex-related bias is limited.
Literature Review
Background
COPD is characterized by persistent airflow limitation which predominately
results from biological processes subsequent to exposure of the lung to environmental
risks, specifically prolonged tobacco smoking and household air pollution (ATS, 2018).
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Obstruction of the airway is a product of tissue destruction, inflammation, and bronchial
narrowing, all leading to the compromised ability of air to move in and out of the lung.
Disease frequently presents as burdensome respiratory symptoms such as shortness of
breath, coughing, and production of mucous leading to significant limitation of activity.
Moreover, faster decline in lung function in these patients is observed. Exacerbations,
periods of disease worsening, are frequent as the airway pathology is altered and can be
easily triggered by common viruses and environmental pollutants.
Prevalence
Global burden of obstructive lung disease is estimated at 251 million cases, of
which, roughly 27 million are in the United States (WHO, 2017). Generally, those of
lower socioeconomic status are more likely to experience disease. Because illness
progresses with symptoms developing over time, without advocacy for population wide
screening, it is difficult to identify cases early.
The effect of COPD expenditures on US healthcare budget is exorbitant. In the
year 2000, there were over 8 million outpatient visits, 1.5 million emergency visits, and
726,000 hospitalizations resulting from COPD (Mannino, 2017). Patients with COPD are
also more likely to be re-hospitalized. Because patients with COPD have multiple
comorbidities, direct and indirect costs are underestimated; patients may be hospitalized
for other reasons which are further complicated by COPD. Patients with COPD have
been reported to have a 22.8% burden of disability than those without, 7.3% (Mannino,
2017); as such, total medical expenditure is higher. End of life care for patients with
COPD frequently requires intensive care, thereby leading to additional assumed costs.
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Small-scale screening interventions have been successful in identifying patients earlier in
the disease process. Broad scale screening programs for patients at risk for COPD may
incrementally increase costs; however, intervention earlier promises to hinder the already
burdensome and expensive trajectories.
Diagnosis and Treatment
GOLD (2018) suggests that patients with known risk and symptoms should
undergo lung function testing, confirming diagnosis and establishing degree of airflow
obstruction. Because breathing abnormalities can have varied pathologies, pulmonary
function testing serves as proper confirmatory procedure. Disease severity is sequentially
established based on degree of airflow obstruction, presence and burden of symptoms and
risk for exacerbations.
Treatment of illness involves two main goals: reducing symptoms and limiting
risks (GOLD, 2018). Nonpharmacologic treatment includes pulmonary rehabilitation as
continuance of physical activity has exhibited positive outcomes in patients (McCarthy,
2015). Pharmacologically, vaccines and inhalations therapies for patients have shown
both an improvement in lung function, reductions of exacerbations, and slowing of lung
function decline (Celli, 2014). Reflecting on pharmacologic treatment patterns in the US,
a tremendous opportunity to optimize exists. Diette and colleagues (2015) observed that
45% of COPD population was receiving maintenance therapy while 69% was on rescue
treatment. It is possible that underdiagnosis and undertreatment are related as one may
lead to the other; however, this is beyond the scope of this investigation. Additional
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research is necessary to understand suboptimal treatment patterns across COPD patients,
specifically, fragile groups such as women and those of lower socioeconomic status.
COPD and Trends in Women
Reflecting on the experience of women within the healthcare system,
disproportionality across therapeutic areas is observed; suggesting that certain chronic
diseases are faced to a greater burden and severity in this patient population (Smith
2013). Agency for Healthcare Research and Quality describes disproportionate trends in
cardiovascular, metabolic, bone, psychiatric and HIV/AIDS in women, emphasizing
nuances detected within female population are unfavorable while calling for much
needed awareness, evidence generation and policy change (AHRQ, 2012). Several
diseases are observed to present differently in women. For example, cardiovascular
disease is the leading killer of men and women alike; however, 42% of women die within
the first year following a heart attack in comparison to 24% of men (Agency for
Healthcare Research and Quality [AHRQ], 2012). Women are more likely to receive
delayed diagnosis and aggressive treatment in comparison to men (AHRQ, 2012).
Observance of these important phenomena, both biologically and socially, have led to
myriad of questions in multiple therapeutic areas with the intent of understanding
causalities and possible opportunities.
Reflecting on current body of evidence specific to COPD patterns, similar
distinctions are observed. While respectable gains through the reduction of COPD
related mortality have been observed in men, the same target have been stagnant in
women (Diaz-Guzman, 2014); COPD is the 4th leading cause of death in the United
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States, however, in women, it’s the 3rd (CDC, 2018). It is also apparent that women,
commonly, have greater morbidity from the illness, defined through a greater utilization
of the healthcare system. Mechanistically, some exploration has been done to understand
the impact of tobacco exposure to the male and female lung. Certain epigenetic
causalities are hypothesized, specifically, maternal exposure to fetus and hormones
(Dransfield, 2006). Causality of maternal tobacco exposure to the fetus increases to the
risk of offspring developing lung disease, severity is greater in female children.
Additionally, certain evidence has pointed to tobacco exposure and sequential pathology.
Interestingly, women cultivate disease with less noxious particle ‘dose’ as compared to
men. A study by Nakano et al. utilized computed tomography techniques evaluating lung
pathology, determining that women had greater pathology compared to men with similar
and even less smoking exposure (Nakano, 2000). These distinctions are important for
research as traditionally randomized trials in COPD require subjects 40 years of age and
greater with 10-year smoking pack smoking history; this evidence suggests that tobacco
exposure for women is potentially less, therefore, a significant proportion of female
patients are under-represented in studies.
Publicly, COPD is accompanied by societal bias. Because the illness is
considered a product of a health hazardous behavior, a perception of “fault” is not
uncommon among society. This sensitivity is potentially detrimental for patients as they
are discouraged from and ashamed to seek care and therefore delay interventions.
Collectively, this is further complicated by an unspoken bias within the healthcare
community possibly affecting both appropriate diagnosis and treatment (Mamary, 2018).
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The majority of research continues to regard COPD as a disease primarily observed in
men. Chapman and Tashkin (2001) said “only 57% of physicians offered COPD as the
most likely diagnosis following presentation of the history and physical
examination…[furthermore] COPD was significantly more likely to be offered as the
provisional diagnosis for the hypothetical male patient than the hypothetical female
patient” (p. 1693). In a recent study by the COPDGene group it was also noted that
women generally manifest greater burden of symptoms and earlier in age as compared to
males (DeMeo, 2018). It is unknown however how presence of symptoms and risk
translate to diagnostic patterns. Aggregating signals point to sex differences in the
prevalence, susceptibility to, severity of, and response to treatment and management of
chronic obstructive pulmonary disease. This gap may be specifically problematic for
women, for example, because they may not be adequately informed of the symptoms of
COPD, appropriately screened for the disease, or receive appropriate interventions and
treatment.
Definitions
Chronic Obstructive Pulmonary Disease (COPD): A common, preventable, and
treatable disease of the respiratory system involving persistent symptoms and airflow
limitations due to airway abnormalities typically caused by prolonged exposure to
noxious particles and gasses (GOLD, 2018).
Gender: Socially accepted characteristic of males and females which involve
physically observable traits, norms, and societal roles (WHO, 2019).
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Gender Bias: In the context of healthcare, gender bias is prejudice in terms of
perceptions
Health Care Resource Use: Consumed services or goods used by patients
resulting from interactions between patients and the healthcare system (Da Silva, 2011).
Pulmonary function testing/Spirometry: A group of breathing tests evaluating air
flow, lung volumes, gas exchange, and inflammatory markers (NIH, 2018).
Sex: A biological characteristic typically assigned at birth describing natural
chromosomal, internal, and external reproductive organs (APA, n.d.).
Smoking Pack History: A calculation of number of packs smoked per day for the
number of years a subject has smoked (GOLD, 2018).
Assumptions
Reflecting on observed prevalence, mortality trends in women, as well as known
generalized perceptions about COPD, subjects’ sex may have an influence on diagnostic
patterns. BRFSS 2017 patient population were queried regarding symptoms of
obstructive lung disease and knowledge regarding COPD according to healthcare
providers. Additionally, subjects reported undergoing breathing testing suggested use of
a screening tool to support the diagnosis as per GOLD recommendations. No known
recall bias was described between males and females pertaining to disease and diagnosis
history; therefore, it was assumed that trend comparison is acceptable.
Scope and Delimitations
Considering the design of the study and nature of the dataset, this examination
was cross-sectional design and descriptive, aiming to determine COPD- related

15
diagnostic patterns, specifically as they are observed between males and females. The
study population included male and female participants who were able to read and write
and therefore could self-report their medical history. The BRFSS 2017 queried
participants in 50 states across the US, the District of Columbia, American Samoa, Palau,
Puerto Rico, US Virgin Islands, and Guam; therefore, the breadth of the patient
population allowed deductions to be generalizable at the national level. The original
dataset enrolled subjects engaging with the survey team, and therefore no selection bias
was observed, and the sample was representative of the general population. For this
analysis, participants were male and female respondents who have been told that they
have COPD and have responded to breathing tests query. Understanding of illness is
complex and can be dependent on perceptions towards disease, access to healthcare, and
biases within the healthcare system, and as such, signals within this investigation were
intended to be descriptive, rather than point to causality. Further exploration of causality
may be warranted, driving potential opportunities for intervention and social change.
Study Boundaries
Selection bias is a significant limitation of this study. As with most secondary
analyses, there is little influence on the study population, constructs collected, and
methodology utilized for collection and data entry; therefore, variable analysis relies on
participant reported history rather than authentic medical record. Original data surveyed
subjects across general health, risks and utilization of resources; COPD being a module
within the general survey, data is not specific towards a targeted COPD population. It is
described that patients may understand, and experience disease differently, therefore may
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not be generalizable to the broader population who is symptomatic, yet not engaging
within the healthcare system for care. Additionally, because BRFSS 2017 is a US
specific dataset, description may only allude to patterns in the US. Utilizing caution
when interpreting these is warranted as subject numbers within the specific nations are
not balanced.
Generalizability and Scope
BRFSS captured survey responses from the broader population of US and its
territories, as such, generalizability of results may be imposed on the general population
within surveyed geography. Because this population is gathered in a non-clinical setting,
trends may be generalizable to mainstream population, as opposed to limiting to only
those seeking care for their illness. Scope of investigation was to subjects who have been
told by healthcare provider that they may have COPD, with rest of the cases excluded to
focus on relevance to research question. Confounders of study include geographical
influences, race-ethnicity, cultural beliefs around COPD, socioeconomic factors,
education, and marital status. With the utilization of the 2017 dataset, previous trends
were not investigated.
Significance of the Study
Significance to Theory
SEM allows for a deconstruction of an observed phenomena across layers of
society. On a macro level, recognizing overall under-diagnosis patterns, particularly as
experienced by women, can guide a shift in public policy towards population screening
and overall stigmatization of this disease. At the core are individual beliefs by both
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clinicians and patients alike. Similarly replacing views of sex bias in prevalence driving
towards timely diagnosis stands the capability to impact interpersonal, organizational and
community norms. The intent is to drive public acceptance and policy around COPD as
it relates to women while synergizing with grass roots efforts on an individual level.
Significance to Practice
Recognizing sheer burden of COPD in the United States, alarming indicator of
staggering under-diagnosis, complicated by societal biases towards disease in women
warrants further investigations in terms of understanding diagnostic patterns and possible
ramifications. Examining time to diagnosis, disease severity upon diagnosis as
experienced by male and female patients can offer necessary evidence to guide further
research and potential intervention across societal sectors with the intent of changing
attitudes and beliefs towards COPD with the anticipated behavior change of timely
diagnosis and population wide screening policy.
Significance to Social Change
The USPSTF has been a loud opposing body to COPD screening programs.
Following their systematic review, the group recommended against screening
asymptomatic patients for COPD, suggesting that benefits do not outweigh risks
(USPSTF, 2016). Their work in evaluating currently available data is respectable yet
fails to consider success and long-term impact of previously executed programs. The
USPSTF, fails to consider the magnitude of undiagnosed COPD patients. An
investigation by Martinez and colleagues discovered that patients who don’t have a
diagnosis have a greater risk of mortality resulting from COPD (Martinez, 2015).
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Reflecting on general epidemiologic trends, impact of delays to diagnosis has also been
correlated to greater morbidity and lower quality of life (Diaz-Guzman, 2014). It must
also be noted that previously executed screening programs in different therapeutic areas
have shown capability to halt these trajectories.
Clearly, this particular issue bears a significant magnitude of scientific merit and
advocacy, yet, has been less than successful in becoming a political priority. Much of
this, possibly, is the discouragement by the USPSTF. Moreover, because screening
programs are expensive, political support and therefore fund allocation is necessary. An
upstream approach to burdens observed resulting from COPD could provide a long term,
sustainable solutions. As such, a consideration and politicization of COPD screening
programs is essential.
Borrowing a page from the history of breast cancer, a leading cause of cancer in
women, much is to be celebrated in the proposal and adoption of Breast Cancer
Screening Programs. Through the work of cross collaborative stakeholders, including the
ACS, guideline agencies, and US DHHS, breast cancer screening policies and sequential
interventions have been successful in identifying early disease in women. Through the
identification of early cases, more women have survived the diagnosis. Similarly,
upstream policies encouraging broad screening for COPD, translated in practice by the
medical and research communities stand the capability of making an impact on the
current trajectories. As is recommended by the GOLD, American Thoracic Society and
European Respiratory Society, pulmonary function testing must be offered to patients
with a risk factor for COPD. Evidence from this investigation can further elevate the
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hypothesized delay to diagnosis as experienced by women, leading awareness,
intervention, policy and social change.
Summary
COPD represents a significant problem to society as the prevalence is high,
heterogeneously impacting the population. Women have been observed to have greater
morbidity and mortality resultant from the illness. Understanding nuances in terms of
confirmatory breathing testing between males and females can offer important insights
regarding practice patterns and potential biases towards illness. Additionally, the impact
of symptoms and healthcare coverage further provides information regarding these
important tests. With prevalence and morbidity trends projected to continue increasing,
while significantly contributing to the already stretched healthcare expenditure budget,
recognizing nuances within the population may serve as a relevant springboard to myriad
of stakeholders. Recognizing sex differences and experience with COPD may further
guide education and advocacy initiatives, perhaps mitigating or preventing previously
engendered societal biases.
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Section 2: Research Design and Data Collection
Introduction
COPD prevalence in the United States is underreported, largely due to
underdiagnoses and barriers toward screening. While some heterogeneity is apparent
within the general population, women continue to experience greater morbidity and
mortality. In the United States, more women die as a result of COPD, a trajectory that has
increased steadily over the last decade (CDC, 2018). The current study intended to
describe use of breathing tests among women who have been told by healthcare providers
they had potential COPD. Acknowledging patterns towards lung function testing can
describe whether a latent sex bias towards this diagnostic and treatment tool exists,
possibly leading towards future exploration and intervention. Section 2 includes;
Research Design and Rationale, Methodology, Population, Sampling and Data
Collection Procedures, Instrument and Operationalization of Constructs, Threats to
Validity, Ethical Procedures, and a Summary.
Research Design and Rationale
This study aimed to describe patterns involving breathing testing between males
and females who have knowledge of COPD. Because spirometry is a key diagnostic tool
and drives treatment decisions, variances based on sex can be instrumental in partially
describing disease outcomes. The independent variable in this study was sex as both men
and women can develop COPD. The dependent variable was use of breathing tests
among the population of subjects who have been told that they may have COPD,
emphysema, or chronic bronchitis. Moderating variables were symptoms such as
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shortness of breath, cough and production of phlegm. Additionally, sociodemographic
factors such as socioeconomic level, education, and presence or absence of healthcare
coverage were considered moderating variables as these can impact access to pulmonary
function testing.
Methodology
Population
BRFSS 2017, collected by the CDC, was the data source utilized for this
secondary analysis. Subjects who had been told they had COPD served as the primary
analysis population. Furthermore, responses to breathing tests module and age parameter
were imposed. Based on the codebook provided by the CDC, final sample size for this
investigation was 6,334 cases.
Sampling and Data Collection Procedures
In order to prevent selection bias, a broad selection strategy was employed by the
CDC for outbound calling to subjects targeted by the BRFSS sampling strategy. The
entire 2017 data set included 450, 016 cases; of these, 37, 577 were told they had COPD.
To further aid in appropriate cohort selection, participants were all older than 35 and had
received breathing tests. Subjects within BRFSS- targeted areas had an equal chance of
being invited to participate in the survey and give consent for participation. The initial
dataset was entered and maintained by the CDC.
Sampling frame. Sampling frame included (a) adults surveyed by BRFSS in
2017, (b) ages 18 years and older, (c) all reported races and ethnicities, and (d) those
responding “yes” to “(Ever told) you have chronic obstructive pulmonary disease,
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C.O.P.D., emphysema, or chronic bronchitis?” (CDC, 2018). The COPD cohort was
extracted from the total population in the database, who have a myriad of non-respiratory
diseases and should not undergo spirometric testing. Sample also excluded younger
cohort (35 years and less) as COPD is unlikely below this age lacking further pathology
(CDC, 2018). Selecting the study population was based on a broad and generic question
such as “having been told of COPD”, provided the best strategy to eliminate bias
introduced by covariates such as severity of disease, incidence of tobacco use, access to
care, environmental exposures and behavioral perceptions as the latter should all be
equally represented within the chosen analysis set. This specific cohort of subjects
underwent described sensitivity testing.
Data accessibility and permission. The BRFSS is an open source dataset and
can be accessed through the CDC website (BRFSS, 2018). Data use agreement described
by the CDC for research purposes and coordinated by the Institutional Review Board
(IRB) at Walden University, described in the ethics section. Primary dataset collected for
the purposes of public health surveillance, so, informed consent was exempt.
Power analysis. Since this was a descriptive cross-sectional analysis, all subjects
meeting the proposed criteria were analyzed and post hoc power analysis was conducted
to confirm that the achieved statistical power was adequate (>80%).
Research Questions and Hypotheses
RQ1: Are there differences in terms of use of breathing tests between men and
women who have been told by clinicians they have COPD?
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Ho1: There are no differences in terms of use of breathing tests between males and
females who have been by clinicians told they have COPD.
Ha1: There are difference in terms of use of breathing tests between males and
females who have been told by clinicians they have COPD.
RQ2: Are there differences in terms of use of breathing tests between men and
women who have been told by clinicians they have COPD and experience cough, phlem,
and shortness of breath?
Ho2: There are no differences in terms of use of breathing tests between males and
females who have been told they have COPD and experience cough, phlem, and
shortness of breath.
Ha2: There are difference in terms of use of breathing tests between males and
females who have been told they have COPD and experience cough, phlem, and
shortness of breath.
RQ3: Are there differences in terms of use of breathing tests between men and
women who have been told by clinicians they have COPD and access to healthcare?
Ho3: There are differences in terms of use of breathing tests between males and
females who have been told by clinicians they have COPD and access to healthcare.
Ha3: There are differences in terms of use of breathing tests between males and
females who have been told by clinicians they have COPD and access to healthcare.
Instrumentation
BRFSS is a publicly funded open source database operationalized by the CDC;
this study used the 2017 survey. BRFSS is populated by random digital dialing across all
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the states and US territories, collecting health related risk behaviors, chronic health
conditions and use of preventive services. The BRFSS completed more than 400,000
interviews per year making it the largest continuously conducted health survey. Such a
database was the optimal tool to answer the research question within this study, due to its
broad US representation, the breadth of captured data and continuous data acquisition,
thus making this generalizable across the US. The BRFSS is used by various stakeholders
and researchers to evaluate behavioral population trends as well as chronic disease
patterns on both state and federal levels.
Operationalization of Variables
Table 1 describes relevant demographic variables explored in this investigation.
Account of age, race/ethnicity, marital status, income and education level will offer
description of patient population of interest.
Table 1
Demographic Variables of Interest
Type of
measurement

Definition

Variable

Age
(confounder)

Nominal

Years of life at
time of survey

3=35-44 years
4=45-54 years
5=55-64 years
6=65 and up

Race/ethnicity
(confounder)

Nominal

Reported race
and ethnicity

1=nonHispanic White
2=nonHispanic Black
3=Hispanic
4=All Others

Marital Status

Nominal

Marital Status

1=Married

Name

(table continues)

25
(confounder)

2=Divorced
3=Widowed
4=Separated
5=Never
married
6=Unmarried

Income
(confounder)

Nominal

Annual
household
income (all
sources)

1=less than
$10,000
2=less than
$15,000
3=less than
$20,000
4=less than
$25,000
5=less than
$35,000
6=less than
$50,000
7=less than
$75,000
8= $75,000 of
more
77=don’t know
99=refused

Education
Level
(confounder)

Nominal

Highest grade
or year of
school
completed

1=never
attended
school, only
kindergarten
2=grades 1-8,
elementary
3=grades 9-11,
some high
school
4=grade 12 or
GED, high
school
graduate
5=college 1-3
years, some
college
6=college 4
years or more,
(table continues)
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college
graduate
9=refused

Table 2 describes variables necessary to operationalize research questions.
Variables include sex, receipt of breathing tests to diagnose breathing problem, and
COPD related symptoms of cough, phlegm, and shortness of breath. Additionally, years
of smoking and access to health insurance will be interrogated as cofounders.
Table 2
Operational Definitions of Variables
Type of
measurement

Definition

Variable

Sex
(independent)

Nominal

Sex of respondent

1=Male
2=Female
9=Refused

Breathing
Tests
(dependent)

Nominal

Given a breathing
tests to diagnose
breathing problems

1=Yes
2=No

Cough
(covariate)

Nominal

Symptoms of
cough on most days
in last 3 months

1=Yes
2=No
7=Don’t
know
9=Refused

Phelm
(covariate)

Nominal

Symptoms of
1=Yes
phlem on most days 2=No
in last 3 months
7=Don’t
know
9=Refused

Shortness of
breath
(covariate)

Nominal

Shortness of breath
when hurrying on
level ground or

Name

1=Yes
2=No
7=Don’t
know
(table continues)
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Health
Insurance
(covariate)

Nominal

Smoking
History
(covariate)

Nominal

walking up
hill/stairs
Presence of health
insurance
(HMO/government)

9=Refused

Lifetime years of
smoking tobacco
products

1-76=Yes
88=Never
smoked, less
than 1 year
77=Don’t
know/not sure
99=Refused

1=Yes
2=No
7=Don’t
know
9=Refused

Independent Variable. In this study, sex was the independent variable. Sex
attributes were obtained directly from the BRFSS database.
Dependent variable. Utilization of breathing tests among the population of
subjects who have been told that they may have COPD, emphysema or chronic bronchitis
served as the dependent variable. Breathing tests construct was obtained in a binary
manner. Cases who had a response of yes or no to this module were selected for analysis
Covariates. The presence of symptoms such as shortness of breath, cough and
production of phlegm, were considered as covariates due to potential influence on driving
medical decision towards a breathing tests. Additionally, presence/absence of health care
coverage can be considered moderating as these can impact access to healthcare
sequentially testing. These variables can be analyzed as partially mediating or completely
mediating based on the static nature of either the independent or dependent variable.
Study population and missing cases. Study population of subjects with
knowledge of COPD, emphysema and chronic bronchitis was isolated from the parent
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2017 BRFSS data set, yielding 37, 577 cases for investigation; described in Table 3.
Further inclusion criteria of age and response to breathing tests module were applied,
Figure 2. Considering no significant missing cases were present within the study
population, no additional mitigation procedure was necessary.
Table 3
Subjects with COPD, Emphysema, or Chronic Bronchitis
Frequency

Percentage

Yes

37,577

8.35

Weighted
Percentage
6.51

No

410,141

91.14

93.00

Don’t know

2,099

0.47

0.46

Refused

197

0.04

0.03

Not Asked,
missing

2

-

-

Data Analysis Plan
Analysis Techniques
All variables used for investigation are nominal, and therefore appropriate
techniques were employed to describe the population while evaluating by SPSS 25
statistical software.
Descriptive statistics. The population of interest was described by assessing
frequencies, proportions, and percentages within the broad cohort of subjects who have
been told they have COPD, emphysema or chronic bronchitis.
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Bivariate analysis. I used bivariate chi-square methodology for RQ1, assessing
relationships between males and females who have received a breathing tests. The
dichotomized phenomena of interest, breathing test, requires Pearson’s chi-square test as
the primary bivariate analysis (Science Direct, 2019).
Multivariable analysis. Multivariate analysis allows for focus on multiple
variables of interest and appropriate methodology for RQ2 & RQ3 in assessing
relationship between opportunity of breathing tests among males and females with COPD
related symptoms and presence of health insurance, respectively. For this test, BLR was
the appropriate methodology (Laerd, 2018).
Rationale for Covariate Inclusion
Inclusion of population demographics such as age, race/ethnicity, income and
level of education as it relates to opportunity towards a breathing tests is a confounding
factor as these may influence health literary and therefore understanding of necessity to
engage with the healthcare system. As important upstream determinants of health,
covariates must be considered within the investigation.
Interpretation of Results
Interpretation of results was based on odds ratios of receiving a breathing tests
between males and females. Secondarily, odds ratios of receiving breathing tests in the
presence/absence of health insurance and applicable symptoms was assessed. Analyses
was considered at 95% confidence intervals. All statistical analysis were performed by
SPSS version 25 available through Walden University.
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Threats to Validity
BRFSS is a comprehensive US generalizable dataset, yet has several limitations
requiring notice. Primarily, subject selection methodology is random to noninstitutionalized adults 18 years and older selected via outbound calling; subjects wishing
not to participate may have unique attributes and are excluded from the dataset.
Additionally, because the variables are collected via self-reported survey, validity of
recall, non-response, health and literacy, missing information may all impact validity of
the investigation.
External Validity
Respective to external validity, broader generalizability of investigation was
considered. With a broad subject footprint across BRFSS collection territories, inferences
drawn from this investigation may describe breathing tests patterns across the US
between males and females while also considering influence by COPD related symptoms
and presence of health insurance. Potential threats to external validity include penitential
selection bias in the subject population as BRFSS is a wide surveillance instrument, as
opposed to a specific COPD focused data set.
Internal Validity
Internal validity assesses the capacity of the data set to accurately support the
research question. In this investigation, due to the survey nature of the data set, subject
recall bias may have posed a potential threat. Additionally, subjects may fail to
accurately understand COPD related questions and either under or over report their
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disease as well as testing and symptomatology. Internal validity was confirmed as much
as possible by using BLR.
Ethical Procedures
This study underwent an expediated Walden Institutional Review Board review
due to the deanonymized nature of the data and lack of active intervention arm (approval
# 08-08-19-0628769). Data were collected by the CDC according to the ICH and broad
clinic research standards. All data were handled in a sensitive and secure manner. There
was no active collection of samples, or identifiable HIPPA protected health information.
All data will be kept in two step authenticated electronic media for 5 years. However,
this is an open source dataset and the integrity of the data is maintained and cannot be
manipulated, creating any additional risk.
Summary
Section 2 described methodological details implicating this investigation. By
statistical testing, signal towards receiving a breathing tests between males and females
was evaluated. Influence of COPD-related symptoms and presence of health insurance as
covariates were assessed. Ethical considerations and mitigations were discussed. In
Section 3, a description of the population and study results are presented.
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Section 3: Presentation of the Results and Findings
Introduction
COPD is prevalent and burdensome, demanding attention from multiple
stakeholders, including patients, families, society, healthcare system, and policy makers.
Even though COPD is non-selective in terms of sex, meaning both males and females can
develop the illness, morbidity and mortality are experienced differently by women
(DeMeo, 2018). In the last decade, there is an observed divergence in mortality resulting
from COPD, with women leading in terms of number of deaths (CDC, 2015). Mainly as a
byproduct of long-standing societal beliefs and perceptions involving tobacco smoking,
females are perceived to be less likely to have COPD then their male counterparts.
Section 3 includes bivariate and chi-square analyses assessing breathing tests trends
among men and women who have been told by a healthcare provider that they have
COPD. Additionally, the influence of common COPD symptoms such shortness of
breath, phlem, and coughing and presence of health insurance were evaluated through
multivariable analysis. Finally, an explorative quasi-simulation of USPTF spirometric
recommendation of active case finding was conducted via chi-square analysis between
males and females who admit to having all COPD-related symptoms. Also, in this
section, a summary of all findings will be included.
Data Collection of Secondary Data Set
CDC coordinated via random telephone samples health-related behavior and
chronic disease data across 50 states and territories by the annual BRFSS. Sampling for
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these data sets involved both land and cellular outbound random calls to
noninstitutionalized adults who were older than 18. The current study used 2017 data.
Time Frame and Response Rates
Data collection for the 2017 cohort was operationalized between January 1 and
December 31, 2017. The Pew Research Center (2012) determined that telephone survey
participation rates continue to decline in comparison to live surveys. CDC has managed
to produce a dataset with comparable and higher than average participation while
balancing representation of landline and cellular participants, with rates of 45.3% for
landline and 44.5% for cellular participants. Furthermore, sample-weighing
methodologies promote overall population appropriateness and overall generalizability.
The total combined BRFSS 2017 sample prior to study cohort extraction was 450,016
cases.
Discrepancies in the Data Set
The original dataset lacked specificity to the research questions respective to
participation in breathing tests as diagnostic procedure for COPD in cases who have been
told that they have the illness. A specific cohort to support analysis was extracted;
inclusion methodologies described in Figure 2.
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Figure 2. Study cohort selection algorithm
From the initial sample, cases who responded ‘yes’ to knowledge of COPD yielded 37,
577 cases, or 8.35% of the cohort. Because screening breathing tests is seldomly utilized
for reasons aforementioned in general practice, and the research question is anchored on
knowledge of this procedure, those cases with the missing/don’t know/refused response
to ‘Have you ever been given a breathing tests to diagnose breathing problems?’ were
extracted, producing 6,501 evaluable cases. Within this cohort, 61.7% were responses
from women; male and female cases were weighed 1:1, giving an equal opportunity for
evaluation between the sexes. Because COPD develops in adulthood, pediatric and
adolescent cases were removed, only allowing participation of subjects 35 years and
older. The final evaluable cohort of n = 6334 was used for analysis.
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Descriptive Demographics and Univariate Analysis of Sample
The study sample demographics are described in Table 4. The majority of the
sample was over the age of 55 and therefore appropriate for the disease under
investigation. While diverse ethnicities are represented, the majority of the sample is
Caucasian. Most of the sample is married, divorced, or widowed. Distribution of income
is heterogeneous, and the sample represents a diverse socioeconomic cohort. A large
proportion of the sample has completed high school and some college.
Table 4
Cohort Demographics
Variable
Age
35-44 years
45-54 years
55-64 years
65 and up
Race/Ethnicity
White
Black
Other, non-Hispanic
Multiracial
Hispanic
dk/refused
Marital Status
Married
Divorced
Widowed
Separated
Never married
Unmarried
Refused
Income
<$10,000
<$15,000

Males

Females
N
(3124)
180
439
847
1659

N
(3129)
178
378
926
1647

%
50.0
5.7
12.1
29.6
52.6

%
50.0
5.8
14.0
27.1
53.1

2538
228
104
83
103
74

81.1
7.3
3.3
2.6
3.3
2.4

2516
261
100
66
113
68

80.5
8.4
3.2
2.1
3.6
2.2

1471
750
401
101
317
75
13

47.0
24.0
12.8
3.2
10.1
2.4
0.4

1038
773
877
131
223
61
23

33.2
24.7
28.1
4.2
7.1
2.0
0.7

225
286

7.2
9.1

321
356

10.3
11.4
(table continues)
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<$20,000
<$25,000
<$35,000
<$50,000
<$75,000
>$75,000
Don’t know
Refused
Education Level
Never attended school,
only kindergarten
Grades 1-8, elementary
Grades 9-11, some high
school
Grade 12 or GED, high
school graduate
College 1-3 years, some
college
College 4 years or more,
college
Refused

404
364
317
384
358
382
211
199

12.9
11.6
10.1
12.3
11.4
12.2
6.7
6.3

377
366
309
310
240
202
402
241

12.1
11.7
9.9
9.9
7.7
6.5
12.9
7.7

4

0.1

6

0.2

157
318

5.0
10.2

131
346

4.2
11.1

1051

33.6

1075

34.4

878

28.0

1006

32.2

708

22.6

549

17.6

13

0.4

12

0.4

General health history and access to healthcare coverage is described in Table 5.
Few participants described being in excellent health. A larger percentage of the
population, ≥ 50% report fair and poor general health. The majority of the cohort, ≥ 90%,
acknowledge some presence of healthcare coverage. The type of insurance is beyond the
scope of this study.
Table 5
Related Health History
Variable
General Health
Excellent
Very Good
Good

Males
N
(3129)
121
389
897

Females
%
50.0
3.9
12.4
28.7

N
(3124)
97
400
864

%
50.0
3.1
12.8
27.6
(table continues)
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Fair
Poor
Don’t Know
Refused
Health Care Coverage
Yes
No
Don’t Know
Refused

930
779
11
1

29.7
24.9
0.3
0.0

994
758
9
3

31.8
24.3
0.3
0.1

2904
221
3
1

92.8
7.1
0.1
0.1

2910
209
2
2

93.2
6.7
0.1
0.1

Table 6 portrays COPD related history of the sample. Unitarization of smoking
tobacco is explained by the lifetime tobacco history of utilization between 1-76 years;
81.3% of males suggest they have smoked within the specified range and only 69.1% of
women. Conversely, 26.1% of the women indicate never smoking, or less than 1-year
exposure, far less than males. A mere 15.4% fit within this description. While this cohort
is all cases who have COPD, far less exposure to tobacco is observed in women.
Table 6
COPD Related History
Variable
Lifetimes Years of
Smoking Tobacco
1-76 years
Never smoked/less than 1
year
Don’t know
Refused
Previous Diagnosis of
Asthma
Yes
No
Don’t Know
Presence of Cough
Yes
No

Males

Females
N
%
(3124)
50.0

N
(3129)

%
50.0

2545
480

81.3
15.4

2161
815

69.1
26.1

99
5

3.2
0.2

139
9

4.4
0.3

967
2132
30

30.9
68.1
1.0

1386
1719

44.4
55.0
0.6

1563
1555

50.0
49.7

1733
1381

55.5
44.2

19
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Don’ Know
11
Presence of Shortness of
Breath
Yes
2230
No
883
Don’t Know
14
Refused
1
Presence of Phlem
Yes
1489
No
1617
Don’t Know
22

0.3

7

0.3

71.3
28.2
0.5
0.0

2428
678
17
1

77.7
21.7
0.5
0.0

47.6
51.7
0.7

1484
1623
16

47.5
52.0
0.5

Far less men, 30.9%, reported a previous diagnosis of asthma in comparison to 44.4% of
women. Shortness of breath appears to be the most commonly described COPD symptom
among men and women, with over 70% of both sexes reporting. Cough and phlem are
experienced by both males and women similarly at over 45% for all.
Representativeness of the Sample
BRFSS 2017 captured landline and cellular phone respondents across all 50 States
as well as US Territories. Within this sample, 8.35% of the cases reported having COPD;
CDC reports state specific prevalence ranging from 5%-9%. This cohort is representative
of national trends. Initial sample overrepresented women, similarly, exhibiting what is
commonly observed. Demographics of the cohort specific to age, socioeconomic status,
marital status, level of education and access to healthcare are all generalizable to
nationally reported data for this patient population (CDC, 2016).
Study Results
Recognizing the observance of COPD related symptoms as well as presence of
healthcare coverage within the sample, inclusion of these constructs within the model is
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justified. The following subsections include statistical assumptions and results of the
three research questions as well as explorative analysis.
RQ1
RQ1 tested for a difference in the utilization of breathing tests between men and
women who have been told by a clinician that they have COPD.
Statistical assumptions. For RQ1, Pearson’s chi-square test was applied. Six
assumptions for a chi-square test are (a) data reported as frequencies or counts, (b)
variables are mutually exclusive, (c) each case may only be counted once, (d) study
groups are independent, (e) variables are dichotomous and categorical & (f) values of cell
expected should be five or more in at least 80% of the cells (McHugh, 2013). All
necessary assumptions for this test are met as data are categorical, mutually exclusive,
cases independently represented, and more than five cell counts are analyzed.
Crosstab and effect size results. Table 7 displays bivariate analysis for RQ1. Of
the overall cohort, 82.56% of the cases have reported participation in a breathing tests.
However, there appears to be a difference in utilization of breathing tests between males
and females, with chi-square p-value approaching significance of p<0.063. To further
support findings from the initial chi-square analysis, Fisher’s Exact Test (utilized to
determine whether a non-random association exists between two categorical variable)
suggested a significant p<0.034. Cramer’s V computation produced an effect size=
0.023, suggesting a moderate association between sex and breathing tests.
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Table 7
Bivariate Characteristics of Breathing Tests Procedure
Received
Tests

Sex
Males

Females

n ( %)

Not
Received
Tests
n (%)

2111
(83.4)

518
(16.6)

2552
(81.7)

573
(18.3)

Χ2

P-value

Fisher’s
Exact

Cramer’s
V

3.444

<0.063

<0.034

0.023
(<0.063)

Figure 3 visually displays responses of males and females respective to experience with
breathing tests. There are less women receiving a breathing tests.

Figure 3. Prevalence of breathing tests between males and females
Hypothesis test results. There is a moderately significant association between
independent variable of sex and dependent variable of participation in breathing tests (χ2
= 3.44, p = 0.063), as displayed in Table 7, thus the null hypothesis for RQ1 is rejected.
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Fisher’s exact test and effect size further support rejection of the null hypothesis
suggesting that there is an association between the variables.
Based on the results of Pearson’s chi-square and Fisher’s exact test, the null
hypothesis is rejected, denotating, there is a difference in terms of use of breathing tests
between males and females, with less women participating in the testing.
RQ2 and RQ3
RQ2 assessed for a difference in use of breathing tests between men and women
who have been told by a clinician that they have COPD and related symptoms (cough,
shortness of breath and phlem).
RQ3 assessed for a difference in use of breathing tests between men and women
who have been told by clinicians that they have COPD and have access to healthcare.
Statistical assumptions. For RQ2 and RQ3, BLR models were used to assess
relevance of COPD-related symptoms and healthcare insurance in terms of access to
breathing tests. These covariates were tested independently and then together to realize
the most appropriate model. Six assumptions for BLR include (a) binary dependent
variable, (b) independents observations, (c) little or no multicollinearity in the
independent variable, (d) linearity of independent variable, and (e) large sample size
(minimum of 500; Statistic Solutions, 2019). All of the necessary assumptions for this
methodology were met, since dependent variable is dichotomous, cases are independent
with no multicollinearity and n=6,334.
BLR results for RQ2. COPD symptoms of cough, shortness of breath and phlem
all displayed a positive significant predictive influence of receiving a breathing tests as is
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evident by positive regression weight (B) and odds ratio (OR), p<0.000. Conversely, a
patient’s sex has a negatively influences receipt of breathing test; females are 15.9%
more likely not to have the breathing tests compared to males (OR=.841, CI 95%: 0.7390.961). Nagelkerke R2=0.044 suggests that model explains roughly 4.4% of the
variability of the outcome. Hosmer Lemeshow of the goodness of fit test produces a
p=0.000, suggesting that the model is a poor fit.
Table 8
BLR for Breathing Tests with Predictors Sex, Cough, Shortness of Breath, and Phlem

B
Sex
-0.173
Cough
0.222
Shortness of Breath 0.485
Phlem
0.187

p
S.E. Wald value
0.068 6.468 0.011
0.065 15.878 0.000
0.053 84.456 0.000
0.049 14.592 0.000

OR
0.841
1.249
1.205
1.623

95% C.I. for
OR
Lower Upper
0.739 0.961
1.119 1.393
1.464 1.800
1.095 1.327

Answer to RQ2. Analyzing results of the binomial regression model, null
hypothesis attached to symptoms of cough, shortness of breath and phelm having no
influence on receiving a breathing tests is rejected; all symptoms have a positive odds of
increasing testing, while sex, in the same model, displays a negative influence.
BLR results for RQ3. Presence of healthcare coverage significantly increases the
odds of breathing tests with OR = 1.741, p < 0.000. As in the original model, sex
displayed a negative influence of OR = 0.883, but this is a marginally significant result (p
= 0.064). Nagelkerke R2=0.012 suggests that model explains roughly 1.2% of the
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variability of the outcome. Hosmer Lemeshow of the goodness of fit test produces a
p=0.003, suggesting that the model is a poor fit.
Table 9
BLR for Breathing Tests with Predictors Sex, and Healthcare Coverage

Sex
Health Care
Coverage

p
B
S.E. Wald value
-0.124 0.067 3.430 0.064
0.554 0.096 33.679 0.000

OR
0.883
1.741

95% C.I. for
OR
Lower Upper
0.775 1.007
1.444 2.099

Answer to RQ3. Null hypothesis of no difference in utilization of breathing tests
in subjects with healthcare coverage is rejected. Health care coverage increases the odds
of testing by 74.1% (OR=1.741, 95% CI: 1.444-.2.099).
Aggregate multivariate regression model. All covariates of sex, COPD-related
symptoms, and presence of healthcare coverage were included in the final analysis, with
results presented in Table 10. All covariates were significantly associated with breathing
tests uptake, with health care coverage having the highest influence (OR=1.747, 95% CI:
1.448-2.107). Nagelkerke R2=0.055 suggests that model explains roughly 5.5% of the
variability of the outcome. Hosmer Lemeshow of the goodness of fit test produces a
p=0.000, suggesting that the model is a poor fit.
Table 10
BLR for Breathing Tests with Predictors Sex, Cough, Shortness of Breath, Phlem, and
Healthcare Coverage
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Sex

B
0.175

S.E.
0.068

Wald
6.544

p value
0.011

OR
0.839

95% C.I. for OR
Lower
Upper
0.074
0.959

Cough

0.224

0.056

15.390

0.000

1.212

1.101

1.335

Shortness of 0.484
Breath

0.053

82.957

0.000

1.622

1.462

1.800

Phlem

0.193

0.049

15.390

0.000

1.212

1.101

1.335

Health Care 0.558
Coverage

0.196

33.976

0.000

1.747

1.448

2.107

Explorative Analysis
The USPTF (2017) suggested that clinicians should utilize active case finding in
patients who have a risk factor for developing COPD and are symptomatic. In this
explorative analysis, from the above cohort, only cases responding ‘yes’ to COPD
symptoms of cough, shortness of breath, and phlem were selected. Through this analysis,
I was able to assess whether the frequency of breathing tests is higher in symptomatic
patients and if the variability in sex is mitigated. Applying supplementary case inclusion
criteria, an explorative analysis produced a sample of n=2100.
Statistical assumptions. For this analysis, chi-square methodology was
implemented; assumptions were previously described.
Crosstab and effect size results. Out of the original cohort of over 6000 cases,
only 2100 reported symptoms of shortness of breath, cough, and phelm. Of these, 88.71%
have had a breathing tests. Applying chi-square testing to assess if there a difference in
the breathing tests participation between symptomatic males and females yields a non-
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significant p < 0.239, further analysis described in Table 11 and Figure 4. Fisher’s exact
test provides a nonsignificant p < 0.241. Cramer’s V computation produced an effect size
of 0.026, suggesting a moderate association between sex and breathing tests.
Table 11
Bivariate Characteristics of Breathing Tests Procedures in Symptomatic Cases
Received
Tests

Sex
Males

Females

n ( %)

Not
Received
Tests
n (%)

893
(89.5)

104
(10.4)

970
(87.9)

133
(12.05)

Χ2

P-value

Fisher’s
Exact

Cramer’s
V

1.384

<0.239

<0.241

0.026
(<0.239)

Figure 4. Prevalence of breathing tests between symptomatic males and females
Answer to explorative analysis. Of the symptomatic patients, a higher
percentage was observed to participate in a breathing tests. Furthermore, previously
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detected differences in terms of tests between males and females was mitigated by the
2

presence of symptoms as suggested by the non-significant χ = 1.384, p = 0.239.
Summary
Section 3 included results and findings of this doctorial research. This segment
reiterated the study purpose, sample selection schematics, cohort demographics, and
COPD-related history and descriptions. This research interrogated the BRFSS 2017
dataset, with participation in breathing tests as the dependent variable and sex, COPD
symptoms, and healthcare coverage as independent variables and covariates.
Significant findings involving female sex negatively associating with breathing
tests were further supported through binomial regression analysis with inclusion of
COPD-related symptoms and presence of health insurance. In a combined model of
select independent variables, odds ratio of breathing tests increased, with health insurance
and shortness of breath being leading influencers. An explorative analysis of
symptomatic adults produced a higher use of breathing tests within this subgroup.
A comprehensive analysis and interpretation of results will be detailed in Section
4. Section 4 offers an overview of analyses, study limitations, recommendations,
applications to theory and literature, and opportunities for social change.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction
The purpose of this quantitative cross-sectional investigation was to assess
breathing tests patterns between males and females with known COPD status. Inclusion
of COPD specific symptoms as well as access to healthcare insurance were also
considered in the model as these covariates may be important in terms of
recommendation for screening. Moreover, COPD-specific symptoms and healthcare
coverage increase the odds of participation in breathing tests in both sexes. Section 4
includes Key Interpretation of Findings, Limitations of the Study, Recommendations for
Future Research, and Implications for Practice and Social Change.
Interpretation of Findings
Analysis of the BRFSS 2017 data set, cases with known COPD and responses to
breathing tests modules, indicated a significant disproportional use of breathing tests
between males and females. Sex was a negative influence on the odds of breathing tests
(OR=0.839, 95% CI: 0.0735-0.959), while symptoms and healthcare coverage were both
positive significant influencers. This combined model revealed healthcare coverage
increasing the odds of breathing tests by 74% (OR = 1.747, 95% CI: 1.448-2.107), and
shortness of breath by 62% (OR = 1.622, 95% CI: 1.462-1.800). In the following
subsections, I will associate findings of the literature and the SEM.
Findings in Literature
An in-depth review of the literature alludes to a broader problem of COPD
diagnostic patterns as nearly half of the 24 million Americans with symptoms of
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obstructive lung disease remain undiagnosed (NHLBI, 2012). Utilization of a breathing
tests as a means of confirmation is similarly deficient. Results of this study propose that
sex may have an influence on attaining a breathing tests in a patient with COPD,
adversely impacting women. Symptoms and favorable access to healthcare add further
weight.
Sex. There is an overall disparity in terms of experience of women with COPD.
Multiple analyses confirm a greater proportion of women are burdened with symptoms of
COPD, experience morbidity at a younger age then men, as have higher overall mortality
due to COPD (DeMeo, 2019). To date, this is the first quantitative analysis explaining
differences in terms of use of breathing tests for women. A secondary analysis of the
BRFSS 2017 dataset including cases with known COPD and responses to breathing test
modules yielded an overall overrepresentation of women with the disease. Cohort was
weighted by sex, allowing for an equal chance of selecting male and female responder.
Overall use of breathing tests in the study sample was 82.56%, higher than what is
reported nationally. Of this group, 83.4% of men received the testing, compared to
81.7% of women.
COPD symptoms. The USPTF (2017) suggested active case finding to be
practiced by clinicians with the intent to identify candidates for COPD screening,
including process of a breathing tests. Symptoms are objective and generally begin slow,
progressing over time; therefore, it may be difficult for the patient to recognize and
further attribute symptoms to COPD (Rennard, 2015). Price et al (2016) said that
patients will report being asymptomatic when questioned about COPD, yet, report
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limitations of activity due to shortness of breath, smoking status, and/or fitness level.
While patients’ perception regarding symptoms and clinicians’ insights involving
potential disease may have diverse variability, the current investigation confirms that
presence of symptoms increases the odds of breathing tests. This finding is suggests that
physician-patient decisions towards spirometry are productive, leading to an increase in
use of these important tests.
Healthcare coverage. In 2010, President Barak Obama signed the Patient
Protection and Affordable Care Act into Law, intending to expand healthcare coverage to
more than 29 million Americans. Those who lack health insurance are less likely to
engage with the healthcare system for preventative and screening measures, as these
services are expensive within the US health care system. Furthermore, lack of health
insurance will lead to delays in sick care, leading to potential detrimental and expensive
outcomes (APHA, 2020). With a myriad of professional societies advocating for
increases in the use of spirometry to adequately screen for COPD, the literature specific
to impact of health insurance on breathing tests is sparse. In this study, presence/absence
of health insurance were included as a covariate in the model, yielding OR = 1.741, p <
0.000 (95% CI: 1.444-2.099), suggesting a patient’s presence of health insurance
increases the probability of receiving breathing tests.
Combined model. Patterns describing receipt of breathing tests to screen for
COPD are complex and overlapping. An aggregated model involving relevant covariates
of symptoms and healthcare coverage was developed. There is no literature available
specifically involving breathing tests; however, results of aggregate multivariable
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analyses clearly indicated that the primary construct of sex and covariates of symptoms
and healthcare coverage had a significant influence on the breathing tests.
Symptomatic cohort. Little evidence is available on the influence of sex on
spirometry. From an older investigation by Chapman et al. (2001) findings described
hypothetical female patients with same impairment and risk as males offered less
opportunity for breathing tests (Chapman, 2001). Because USPTF active case finding is
heavily weighed on symptoms, it is of interest if sex biases persist among symptomatic
patients. In this study, the symptomatic cohort is smaller (n=2100) displayed an overall
higher utilization of breathing tests. Moreover, the differences observed between the
sexes are no longer significant. This result is different than what was described by
Chapman in 2001 in that both symptomatic males and females are equally participating in
this procedure. It is promising that nearly 19 years of knowledge and advocacy focused
on identifying COPD within population has brought symptoms to the forefront of aiding
disease screening.
Findings to Social Ecological Framework
In this study, SEM was implemented to organize attitudes and beliefs towards
breathing tests in cases with known COPD. Biases in terms of public policy are beyond
the scope of this study; however, trends and inferences can be drawn. On an individual
level, at the core of the SEM, patients’ beliefs and health literacy may drive their
understanding and actions towards engaging with the healthcare system. While the
results of this study are not causative, it is apparent that women in the COPD cohort are
participating in breathing tests less than males; this may be influenced by differences in
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perspectives and action at the individual patient level. For example, women may consider
their symptoms to result from being out of shape, possibly neglecting their previous
smoking history, while males are more likely to correlate smoking with symptoms,
seeking care. Long-standing perceptions of the medical community considering maledominated diseases may similarly influence recommendations to partake in tests.
Broadening the findings to the interpersonal, organizational, and community levels, both
individual and societal influences may shape how both patient groups and care providers
gather COPD information. Even though COPD is prevalent, burdensome, and costly to
the system, wider screening policy is lacking. Early case finding regarding patients at risk
with symptoms mitigated sex biases observed in this heterogeneous cohort. This may not
serve younger patients and women where symptoms can be correlated with other
impairments.
Access to healthcare was explored as a covariate within the study as literature has
suggested that absence of health insurance can deter engagement with the healthcare
system and decision to screen. These barriers can inhibit individual level decisions,
spanning to systemic levels, selecting to recommend testing to patients based on health
insurance access. Results from this study suggest presence of health insurance, in simple
model with just sex as a construct and those more complex inclusive of COPD
symptoms, increase probability of acquisition of breathing tests. Similarly, existence of
health insurance may influence multiple levels within the SEM.
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Summary of Key Findings and Interpretations
From the BRFSS 2017 survey, a cohort of cases with knowledge COPD and
response to breathing tests module produced an overall breathing tests participation rate
of 82.56%. Bifurcating these into male and female categories, a moderately significant
divergence was identified, negatively affecting women. Introducing COPD-specific
symptoms and presence of health insurance into a regression model further reinforced
influence of symptoms and presence of health insurance the likelihood of breathing tests.
In an explorative analysis, breathing tests participation between males and females
among symptomatic cases reveled differences in rates between the sexes were alleviated.
Limitations of the Study
An appreciation of study limitations is necessary as results need be interpreted
with caution when considering generalizability, validity, and reliability. An important
limitation of this study is the data sample, BRFSS, which is produced from a large
population-based survey. As a general random sample, cases are not selected to represent
a particular disease, therefore, query concerning specific screening procedure may
introduce a challenge with health literacy and recall bias resulting from self-reporting by
the participants. Without an exact medical record capturing a diagnosis code and
breathing tests procedure code, it is difficult to ascertain whether in fact the tests was
performed, and if, upon diagnosis. As such, results are reliant on the subjects’ ability to
adequately recall, understand disease in question and sequential testing and symptom
modules affiliated.
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Another limitation of the presents study was that the regression models had a poor
fit, based on the values from the Nagelkerke and Hosmer Lemeshow tests. These findings
underpin the complexity of the disease, social and medical constructs contributing to the
testing decision. Therefore, future research must work towards a larger sample size and
consideration of inclusion of additional variables such as type of insurance (Medicare
versus private), age and education level of the patient. While these constructs were
assessed by descriptive analysis, supplying demographics of the cohort, inclusion of these
variables into the research question, and therefore statistical analysis, may offer a
potentially closer model on influence towards receiving a breathing tests.
An ecological fallacy is possible as multilevel information is aggregated and the
sample is heterogeneous. Furthermore, consideration of the sample size must be noted,
following application of inclusion criteria, previously described, a small sample of cases
was utilized, therefore interpretation of statistical testing must be hypothesis generating
and requiring further investigation in a larger cohort. Finally, the findings of this study
should be limited to the US and its territories due to the demographic of the original
sample, and therefore may not be generalizable to global trends.
Implications for Professional Practice and Social Change
There are several lessons from this study demanding further investigation and
intervention. Recognizing that COPD is burdensome to patients, their families and
society at large, its necessary to recognize that varied groups may experience this disease
differently; therefore, our approach to improving outcomes must be heterogeneous
enough to differentiate and support these nuances. To date, this is one of the first
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quantitative studies which has specifically focused on the COPD breathing tests
experience of women in comparison with men, adding context to practice and society
while laying foundation for future research.
Professional Practice
Learning from historical examples in other therapeutic areas, it is clear that
prevention of disease and education on wellness is far more beneficial than battling an
established chronic illness. The next best scenario, early identification, allows for
education on potential risks, hazards, coaching on lifestyle, habit modification and
potential therapeutic intervention. Conversely, a delay in diagnosis may lead to disease
progression, morbidity, disability and potentially death. In the case of COPD, the
pressing underdiagnosis is concerning, as is the, is the experience of the disease by
women. As is signaled by this study, women with COPD are participating in breathing
tests less than men; in addition, a presence of symptoms increases the potential of
breathing tests. The medical community begins to consider diagnosis of COPD in the
middle ages; however, women are far more symptomatic earlier in life (DeMeo, 2019).
Taking lessons from this study, recommendations can be implemented by
practitioners, while additional evidence needs to be generated by the research
community. Continuing to focus on early disease identification, training modules via
continuing medical education (CME) should be updated describing COPD related trends,
specifically elevating differences in disease presentation, onset of symptoms while
brining attention to potential delay to breathing tests in women. These modules can serve
as productive medium to update provider understanding of COPD, elevating
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heterogeneity of disease and variability in men and women. Anchoring on the
constructive influence of symptoms on probability of receiving breathing tests, utilization
of symptom impairment validated questionnaires such as COPD Assessment Test (CAT)
can further guide productive discussions between clinicians and patients. Symptom
questionnaires can be a helpful tool for both patients and clinicians alike, elevating
presence and burden of symptoms, thereby paving the way towards a productive and
targeted conversation during a clinical visit.
Additional research is necessary to further explore screening disease patterns in
COPD, with a focus on women. Identifying a COPD specific database, ideally one with
health care records and claims available, can offer direct analysis of diagnosis and
procedure codes, thereby reducing certain limitations and greatly increasing reliability of
these findings. Additionally, it would be prudent to also peel away at the causative
perceptions of COPD by clinicians and patients, offering greater understanding and
opportunities of interventions. Employing qualitative methodologies of direct interviews
and focus groups among societal segments of clinicians and patients with and without
disease should offer basis of attitudes and beliefs towards COPD and screenings. Finally,
a mixed methods approach of interviews with clinicians coupled by analysis of actual
practice patterns would be of interest as perceptions and behaviors must be evaluated
concurrently, identifying inconsistencies.
Contribution to Social Change
Application of knowledge in the direction of social change stands the capability to
alter trajectories for society on a broader scale. In the United States, a general
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stigmatization towards COPD exists and is a product of strong rooted beliefs of tobacco
utilization. Because the most significant risk factor for developing COPD in the
developed world is an ongoing decision to engage in a health hazardous activity of
smoking cigarettes, less empathy, sensitivity and ultimately attention may be given to
addressing symptoms. Moreover, individuals who have symptoms could be reluctant to
elevate these for the fear of guilt and shame that may precipitate. In the case of women,
these beliefs are further complicated by previously described entrenched viewpoints on
smoking by women and disease patterns. Insights from this study elevate inclinations
warranting social attention and change.
While breathing tests participation rates in this COPD cohort was relatively high,
over 80%, these results are much higher than what is anticipated in practice. With nearly
12 million Americans with symptoms of obstructive lung disease yet lacking appropriate
diagnosis, ongoing and catalyzed advocacy is essential to elevate COPD as an agenda
item for health advocates and policy makers. Recognizing that experience of COPD is
different in women than men, a change in the perceptions is necessary across societal
levels. Starting broadly, society must recognize that COPD, much like any other chronic
illness, is burdensome, leading to struggle and disability by the patients while adding a
strain on families and the healthcare system. Disassembling biases through the means of
education, working towards awareness can reduce the negative stigmatization towards
COPD as a whole. Attention heterogeneity of disease and experience of women must
similarly take focus and pave the way towards acceptance of prevalence in women.
Considering that both males and females have a higher probability for receiving tests if
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symptoms are present, a raised focus on awareness of symptoms by the medical
community may support more case finding and identification of patients. On a policy
level, professional society and USPTF must re-visit definition of active case finding, with
potential discussion into the variability of experience by women. Translating these
messages to the organizational levels, medical communities should be more vigilant in
recognizing that disease may present slightly differently in women therefore both male
and female patients at risk with symptoms may be warranted for breathing tests.
Social change stands a better opportunity of success when patients are involved
and leading the charge. Working through biases that individual patients may be
experiencing, advocacy and education initiatives within patient communities may lift
some perceptions, perhaps leading to greater initiative by the patients to screen and have
more direct conversations with their providers. Large patient advocacy groups such as the
COPD Foundation can engage and message patient communities in that both men and
women can develop COPD. Again, because results of this study suggested that when
patients have symptoms probability of breathing tests is higher, we must educate patients
to have greater awareness of their symptoms, correlate to potential disease, and
communicate their experience to the healthcare team. An amalgamation of enhanced
awareness and understanding by the healthcare community alongside engaged and health
literate patients can be changes necessary to alter trajectories in COPD for all of society.
Conclusion
This study identified differences in rates of breathing tests usage among male and
female patients who have knowledge of COPD. When symptoms and healthcare coverage
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were added into a multivariate regression model, all had a positive influence on the
prevalence of breathing tests. A larger and more targeted COPD sample with access to
medical records would offer a comprehensive database for quantitative analysis;
specifically, prevalence of breathing tests use among males and females. Furthering
testing regarding practice patterns between men and women patients with COPD can
offer insights to policy makers, health advocates, practitioners, and community where
areas for intervention can offer opportunities to improve identification and ultimately
care for this fragile group.
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